Dr. Ananda Prasad

(Specialst in the role of zinc in the human metabolism)

The following is merely information - not advice. If you need medical advice, please consult your doctor or other appropriate medical professionals.


Webinar: Early Covid Treatments

Presented by - www.cmnnews.org (Covid-19 Medical Network Ltd)

12th December 2020 | 56 mins 04 secs

The Covid Medical Network is making efforts to bring to light the early treatment options for Covid-19 that appear to be ignored or even obstructed by our government, its experts, our health ministers and even our equivalent to the US FDA our TGA.

I personally place a lot of blame at the feet of our national clinical evidence taskforce that has chosen to look at less than 10% of available clinical studies and papers for antiviral treatments and in doing so has completely ignored early treatments. I believe they should have been looking into what works rather than placing a focus on what cannot work.

This presentation seeks to provide you a key understanding of the true science behind available early treatments as well as seeking to bring to light the success of these treatments that appear to be of little interest to our mainstream media yet can save the lives of our most at risk loved ones.

With this webinar, we present Dr Ananda Prasad, a true treasure in the world of medicine.

Aged 92, in this interview, Dr Prasad explains how he drew upon medical knowledge dating back as far as 1869 along with his keen observation to unlock the role of zinc and its importance in both human growth its importance in cell mediated immunity.

This interview is perhaps the most compelling evidence demonstrating just how well founded the theory is behind the current key antiviral components of early treatments that are currently not allowed in Australia.

Our thanks to Steven Bancroft who helped facilitate this interview. Steven, a pastor who was a theologian in residence at the church Dr Prasad attended formed a strong relationship with Dr Prasad. Through a 15 years’ strong friendship, he took a keen interest in Dr Prasad's work and assists Dr Prasad particularly where Dr Prasad's eyesight might not be quite up to the task at hand.

In 1959, when he was 31, Dr Prasad went to Shiraz, Iran as a visiting professor.

He was presented with a 21 year old patient that looked more like a 10 year old boy.

He presented as severely anemic (lacking enough healthy red blood cells to carry adequate oxygen to your body's tissues) - initial diagnosis would point to Iron Deficiency).

As there was no blood loss, this was a hint it was dietary.

Understanding the diet of the region, being a very basic high phosphate diet that was lacking any meat, Dr Prasad could see conditions were a recipe for both iron and zinc deficiency (apparently a high phosphate diet absorbs bot iron and Zinc - chelates it).

Dr Prasad asked if there were many cases like this young man and was told there were as many cases as cared to take on.

With a strong knowledge of prior studies on animals, Dr Prasad was aware that iron deficiency could not account for the growth retardation.

From an understanding of papers dating back as far as 1869, Dr Prasad was aware that zinc was known to affect the growth in fungi, plants, rats and even pigs.

2 years after arriving in Iran, Dr Prasad wrote a paper that proposed that the syndrome he was presented with was caused by iron and zinc deficiency, where the retardation was affected by the zinc.

A key additional observation of Dr Prasad's was that there were no adults with this syndrome older than 25. He was advised that they all died early because of various infections. This observation led to his hypothesis that cell mediated immunity was also affected by zinc.

Later working in Egypt, Dr Prasad found this same syndrome prevalent.

Fast forward to 1984, Zinc was studied on its effects on the common cold.

In his subsequent randomized double blinded clinical trials with Zinc, Dr Prasad found that zinc would reduce the severity and length of the common cold provided zinc was given within 24 hours of the onset of the common cold in a format that could be absorbed and in a frequency that would insure the zinc cupdate. This need for "early treatment" with zinc echoes today with doctors around the world recognizing that the efficient therapies involving zinc need to be done at the early (outpatient) stage.

In March 2020, Dr Prasad and his wife came down with Covid-19.

Dr Prasad put his theory to the test on himself and his wife. With Zinc uptake being critical to the efficacy of zinc in combatting the replication of the virus in the cells, Dr Prasad sought out emerging work in South Korea on Zinc ionophores.

His conclusion like so many other doctors now was without doubt, Hydroxychloroquine was an ideal, safe candidate.

With the Henri Ford institute setup to do a random clinical trial involving zinc and HCL, Dr Prasad was blocked mid-way by the FDA who cited a paper published in the Lancet, one that was subsequently withdrawn in disgrace and exposed for inclusion of fraudulent data and false safety claims of HCQ.

To this date the FDA still has blocked the clinical trial using HCQ.

It is very strange how the FDA allowed the use of HCQ in so many other late-stage trials without zinc where one might predict such a protocol with the absence of zinc and not applied early would simply fail.


We are a group of senior medical doctors and health professionals who are concerned about the health impacts of the lockdowns used in response to the SARS-CoV-2 outbreaks in Victoria and across Australia.

We are also concerned about the lack of good information available to the general public and the misleading use of data. These factors have created an unwarranted state of fear in our community.

We aim to detail the harms of the lockdowns, describe clearly the virulence and risks of the SARS-CoV-2 virus, critique aspects of the management policies and make this information readily available to the general public.